Investor Presentaiton
Investor presentation
ADA 2019
The PIONEER programme showed consistent statistically
significant reductions in HbA1c and body weight
Oral semaglutide lowered HbA1c by 1.0-1.8%-
points by end of trial¹
Mean change in HbA1c (%-points)
Oral semaglutide lowered body weight by
~2-5 kg by end of trial¹
Slide 14
Mean change in weight (kg)
PIONEER trials
1 2 3
4
5 6 7 8 9
10
1
2
3
4
PIONEER trials
5 6
7 8 9 10
0.0%
0+
-1
-0.5%
-1.0%
-2
-3
-1.9*
-2.9 *
-1.2%*
-2.8*
-4
-3.5*
-1.4%*
-3.7*
-4.1
-1.5%*
-5
-4.2*
-4.7*
-4.3*
-1.8%*
-5.0*
-6
-1.0%*
-1.1%*
-1.1%*
-1.5%
-1.3%*
-1.2%*
-1.5%*
-2.0%
1 Hypothetical estimand, Mixed Model for Repeated Measurement (MMRM)
* Statistically significant vs comparator (vs placebo in PIONEER 1; vs empagliflozin 25 mg in PIONEER 2; vs sitagliptin 100 mg in PIONEER 3; vs VictozaⓇ 1.8 mg in PIONEER 4; vs placebo in PIONEER
5; vs placebo in PIONEER 6; vs sitagliptin 100 mg in PIONEER 7; vs placebo in PIONEER 8; vs VictozaⓇ 0.9 mg and placebo in PIONEER 9; vs 0.75 mg dulaglutide in PIONEER 10)
Note: Results shown are: PIONEER 1 and 5 for 26 weeks with 14 mg oral semaglutide, PIONEER 2, 4, 8, 9 and 10 for 52 weeks with 14 mg oral semaglutide; PIONEER 3 for 78 weeks with 14 mg oral
semaglutide; PIONEER 7 for 52 weeks with a mixed dose; PIONEER 6 following occurrence of 137 MACE with a median follow-up time of 16 months.
MACE: major adverse cardiovascular events; FDA: The US Food and Drug Administration
novo nordiskView entire presentation